Clinical trial
A Phase II Trial of 5-Azacytidine (NSC #102816) and Ethyol (Amifostine) in the Treatment of Adults With Myelodysplastic Syndromes
NCT00005598 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of 5-Azacytidine (NSC #102816) and Ethyol (Amifostine) in the Treatment of Adults With Myelodysplastic Syndromes
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2000
- Completion date
- March 31, 2002
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.